CancerSHY-ONC6 effects tumor regression via 19S inhibitionShy Therapeutics LLC has developed and presented data for SHY-ONC6, a novel inhibitor of the proteasome 19S regulator particle (RP) ATPases for the potential treatment of hematological malignancies such as multiple myeloma and mantle-cell lymphoma, as well as solid tumors.